A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Terminated · Phase 1, Phase 2 · NCT05255601
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
At a glance
- Research payments reported, 2025
- $123,572
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 5
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Relatlimab (drug), Nivolumab (drug)
- Dates
- Started 2022-09-13; completion 2025-12-03
- Results posted
- Yes
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
From ClinicalTrials.gov, last updated 2026-06-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $123,572 in research payments for this study in 2025 (11 payments).
Products named: Opdualag, Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ana C. Xavier, MD Pediatric Hematology & Oncology · Birmingham, AL
- Alexandra M. Walsh, M.D. Pediatric Hematology & Oncology · Phoenix, AZ
- Lianna J. Marks, MD Pediatric Hematology & Oncology · Palo Alto, CA
- Stephanie A. Massaro, M.D., M.P.H. Pediatric Hematology & Oncology · New Haven, CT
- Matthew B. Henderson, D.O. Pediatric Hematology & Oncology · Orlando, FL
- Emad Salman, M.D. Pediatric Hematology & Oncology · Ft Myers, FL
- Stacy L. Cooper Pediatric Hematology & Oncology · Baltimore, MD
- Peter M. Gordon, MD, PHD Pediatric Hematology & Oncology · Minneapolis, MN
- Betty L. Herrington, MD Pediatric Hematology & Oncology · Jackson, MS
- Mitchell S. Cairo, MD Pediatric Hematology & Oncology · Hawthorne, NY
- Eric J. Lowe, M.D. Pediatric Hematology & Oncology · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Johns Hopkins University $46,517
- Adventhealth Orlando, FL $18,500
- New York Medical College $17,552
- Stanford University Board of Trustees $11,200
- Regents of the University of Minnesota $8,688
- Lee Daeyeol Mms $7,710
- Phoenix Children's Hospital, AZ $6,850
- University of Mississippi Med Center, MS $4,300
- Lee Memorial Hospital, FL $1,800
- Childrens Hospital of the Kings Daughters Inc, VA $228
- University of Alabama at Birmingham (uab) - Children's Hospital - the Alabama Center for Childhood C $228
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.